Navigation Links
Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:6/16/2009

intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that dose-limiting toxicities may be experienced in future stages of the trial that will use higher doses of Cotara or the risk that results from larger trials may not be consistent with the results of earlier stage trials. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contac
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... July 3, 2015 ... september 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet ... finder sted i Wien ... af internationale forskere og videnskabsmænd foretaget af ... største udfordringer for sundhedsvidenskaben manglen på incitamenter ...
(Date:7/2/2015)... 2, 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an ... monetization of intellectual property, today announced a litigation update. ... v. Verizon Services Corp. et al. , Case No. ... Eastern District of Virginia , the ... interpreting certain key claims in favor of the Defendants ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... July 1, 2015   Decision Resources Group ... advantages of Otezla are its oral administration, alternative ... reported by surveyed rheumatologists. Otezla was the first ... treatment of active psoriatic arthritis in ... of care includes conventional oral treatments including disease-modifying ...
Breaking Biology Technology:Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3
... at Rensselaer Polytechnic Institute have developed a new method ... to hasten the creation of self-powered microsensors for more ... Professor Nikhil Koratkar, the researchers investigated how the flow ... could generate small amounts of electricity. The research team ...
... DIEGO, July 19, 2011 BioMed Realty Trust, Inc. (NYSE: ... entered into a new $750 million unsecured revolving credit facility, ... maturity date of August 1, 2011.  The new facility matures ... year to July 13, 2016 at the company,s option.  In ...
... 2011 The Foundation for Biomedical Research (FBR) announced ... a new novel, UNCAGED . The politically-charged biomedical ... rights extremists unlawfully manipulate public opinion and successfully shut ... country exposed to an international bioterrorism plot that threatens ...
Cached Biology Technology:New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 2New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 3BioMed Realty Trust Enters Into New $750 Million Unsecured Revolving Credit Facility 2BioMed Realty Trust Enters Into New $750 Million Unsecured Revolving Credit Facility 3New Thriller Exposes International Bioterrorism Plot that Leaves the Human Race on the Brink of Certain Disaster 2
(Date:6/16/2015)... 2015 Fingerprint Cards (FPC) raises the ... will amount to at least 340 MSEK to that it ... increase in market growth and orders received the revenue guidance ... revenue for 2015 will exceed 1,500 MSEK to an updated ... MSEK. Due to receipt of orders of touch ...
(Date:6/15/2015)... June 15, 2015 A new report ... reveals the majority of US consumers using mobile banking applications ... such as fingerprint and voiceprint, instead of having to prove ... to Telstra,s " Mobile Identity   -   The Fusion ... with smartphones now the primary channel used by Gen X ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... patent to electronically capture, analyze and identify participants ... recognition methods. This system can: ... an enrollment and subsequent sign-on process is actually ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... of obesity and vitamin D deficiency may put people at ... according to new research from the Drexel University School of ... Diabetes Care. Insulin resistance is a major risk factor ... adults and is the seventh leading cause of death in ...
... scaffolds thousands of times smaller than a human hair to ... lining of elbows and knees that often wears thin from ... Proceedings of the National Academy of Sciences , investigators produce ... models. While the findings are still years away from use ...
... of the Japanese tree frog have learnt not to use ... can distinguish between them. Scientists at the Polytechnic University of ... an algorithm that assigns colours to network nodes an ... How can network nodes be coloured with the least ...
Cached Biology News:Obesity plus low vitamin D may add up to a greater risk of diabetes 2Nanoscale scaffolds and stem cells show promise in cartilage repair 2Nanoscale scaffolds and stem cells show promise in cartilage repair 3Frog calls inspire a new algorithm for wireless networks 2
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
Request Info...
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: